Insmed Incorporated logo
Insmed Incorporated INSM
$ 136.0 -5.56%

Annual report 2025
added 02-19-2026

report update icon

Insmed Incorporated Income Statement 2011-2026 | INSM

Annual Income Statement Insmed Incorporated

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

31.6 B 13.7 B 3.82 B 2.48 B 2.68 B 3.49 B 1.76 B 1.91 B 1.75 B 869 M 774 M 666 M 731 M 162 M 113 M

Shares

199 M 164 M 140 M 123 M 112 M 97.6 M 84.6 M 76.9 M 66.6 M 61.9 M 58.6 M 43.1 M 35 M 26.5 M 23.3 M

Historical Prices

159 83.3 27.2 20.2 23.9 35.8 24.9 29.6 24.2 15.9 12.2 18.5 20 6.16 4.26

Net Income

-1.28 B -914 M -750 M -482 M -435 M -294 M -254 M -324 M -193 M -176 M -118 M -79.2 M -56.1 M -41.4 M -59.7 M

Revenue

606 M 364 M 305 M 245 M 188 M 164 M 136 M 9.84 M - - - - 11.5 M - 4.42 M

Cost of Revenue

123 M 85.7 M 65.6 M 55.1 M 44.2 M 39.9 M 24.2 M 2.42 M - - - - - - -

Gross Profit

- - - - - - 112 M 7.41 M - - - - - - 4.42 M

Operating Income

-1.25 B -878 M -710 M -457 M -375 M -265 M -235 M -307 M -189 M -173 M -117 M -87.4 M -55 M -42.4 M -61.7 M

Interest Expense

83.8 M 84.9 M 81.7 M 26.4 M 40.5 M 29.6 M 27.7 M 25.5 M 5.92 M 3.5 M 2.89 M 2.42 M 2.41 M 763 K 10 K

EBITDA

-1.24 B -872 M -704 M -452 M -366 M -256 M -230 M -306 M -186 M -171 M -116 M -86.3 M -54.3 M -41.9 M -35.4 M

Operating Expenses

- - - - - - 348 M 315 M 189 M 173 M 117 M 87.4 M 66.5 M 42.4 M 40.1 M

General and Administrative Expenses

701 M 461 M 345 M 266 M 234 M 204 M 211 M 168 M 46.2 M 35.3 M 30.6 M 23 M 22.2 M 12.7 M -

All numbers in USD currency

Quarterly Income Statement Insmed Incorporated

2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

189 M 181 M 179 M 174 M 155 M 148 M 148 M 143 M 138 M 136 M 136 M 121 M 120 M 119 M 119 M 117 M 110 M 103 M 103 M 102 M 96.6 M 89.8 M 89.7 M 89.2 M 81.8 M 77.5 M 77.3 M 77.1 M 76.8 M 76.6 M 76.6 M 65.3 M 62.2 M 62 M 62 M 61.9 M 61.9 M 61.9 M 61.8 M 61.8 M 60.8 M 50 M 49.8 M 44.1 M 39.3 M 39.2 M 39.1 M 37.4 M 31.8 M 31.6 M 31.5 M 25 M 24.9 M 24.9 M 24.8 M 24.8 M 24.8 M 18.8 M

Net Income

-322 M -257 M - -221 M -301 M -157 M - -159 M -245 M -160 M - -131 M -95.6 M -94.6 M - -113 M -117 M -91.6 M - -63.7 M -61.9 M -66.4 M -53 M -60.7 M -66.5 M -74.2 M -91.6 M -87.7 M -76.4 M -68.5 M -65.4 M -45.2 M -44.7 M -37.4 M -68.4 M -37.8 M -36.6 M -33.5 M -31.2 M -31 M -28.6 M -27.4 M -17.6 M -24 M -23.2 M -14.3 M -16.2 M -17.3 M -8.85 M -13.7 M -15.5 M -9.38 M -9.7 M -6.84 M -8.16 M -34.6 M -10 M -6.89 M

Revenue

107 M 92.8 M - 93.4 M 90.3 M 75.5 M - 79.1 M 77.2 M 65.2 M - 67.7 M 65.2 M 53.1 M - 46.8 M 45.4 M 40.2 M - 43.6 M 42.5 M 36.9 M 45.7 M 38.9 M 30 M 21.9 M 9.84 M - - - - - - - - - - - - - - - - - - - - - 11.5 M - - - - - 1.4 M 435 K 978 K 1.6 M

Cost of Revenue

28.1 M 21.3 M - 21.2 M 21 M 17.5 M - 16.7 M 16.6 M 13.8 M - 13.5 M 16.4 M 12.2 M - 10.2 M 10.8 M 9.84 M - 10.6 M 9.95 M 8.44 M - 6.44 M 4.92 M 4.15 M 2.42 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Gross Profit

- - - - - - - - - - - - - - - - - - - 33 M 32.5 M 28.4 M 37 M 32.4 M 25.1 M 17.8 M 7.41 M - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

Operating Income

-313 M -248 M - -213 M -289 M -146 M - -148 M -236 M -148 M - -128 M -88.3 M -89.8 M - -104 M -88.6 M -83.8 M - -56.2 M -54.1 M -60.4 M -47.1 M -56.5 M -62.2 M -69.5 M -87.7 M -84 M -72.9 M -62.8 M -65.4 M -44.1 M -43.5 M -36 M -67.1 M -37.1 M -36.1 M -33.1 M -32.6 M -30.2 M -28 M -26.7 M -23.1 M -23.4 M -22.8 M -18.1 M -15.6 M -16.8 M -8.27 M -14.3 M -15.8 M -9.35 M -9.98 M -7.26 M -8.87 M -35 M -10.5 M -7.42 M

Interest Expense

21.2 M 21.6 M - 21.1 M 21.3 M 21 M - 20.3 M 20.6 M 20 M - 3.35 M 3.36 M 3.29 M - 11.2 M 10.3 M 7.56 M - 7.18 M 7.47 M 7.41 M - 6.85 M 6.78 M 6.73 M - 6.68 M 6.49 M 5.64 M - 1.5 M 1.49 M 1.47 M - 769 K 624 K 622 K - 725 K 718 K 722 K - 594 K 595 K 606 K - 525 K 635 K 643 K - 222 K 1 K 2 K - 2 K 3 K 4 K

EBITDA

-312 M -246 M - -212 M -288 M -144 M - -146 M -234 M -147 M - -126 M -87.1 M -88.5 M - -96.6 M -87.3 M -81.4 M - -49.4 M -49.6 M -58.1 M -47.1 M -53.2 M -59.9 M -68.4 M -87.7 M -81.3 M -71.2 M -62 M -65.4 M -41.9 M -42.1 M -35.3 M -67.1 M -35.4 M -35.1 M -32.6 M -32.6 M -28.9 M -27.1 M -26.3 M -23.1 M -22.7 M -22.5 M -17.9 M -15.6 M -16.4 M -7.97 M -14.2 M -15.8 M -8.94 M -9.71 M -7.13 M -8.87 M -34.7 M -10.3 M -7.34 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - - - 84 M 72.9 M 62.8 M - 44.1 M 43.5 M 36 M - 37.1 M 36.1 M 33.1 M - 30.2 M 28 M 26.7 M - 23.4 M 22.8 M 18.1 M - 16.8 M 19.8 M 14.3 M - 9.35 M 9.98 M 7.26 M - 35.4 M 11.5 M 9.02 M

General and Administrative Expenses

155 M 148 M - 119 M 107 M 93.1 M - 90.6 M 84.4 M 79.9 M - 75.6 M 60 M 56.7 M - 60.3 M 57.2 M 51.6 M - 46.6 M 49.7 M 51.3 M - 53.3 M 52.4 M 54.8 M - 44.4 M 37.2 M 32.7 M - 17.4 M 16.6 M 13.7 M - 13.7 M 12.3 M 12.5 M - 11 M 9.71 M 9.54 M - 8.2 M 7.87 M 6.73 M - 4.75 M 7.54 M 3.98 M - 3.65 M 2.24 M 2.52 M - 2.47 M 2.74 M 3.26 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company Insmed Incorporated (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Assembly Biosciences Assembly Biosciences
ASMB
$ 28.46 3.45 % $ 319 M usaUSA
Ascendis Pharma A/S Ascendis Pharma A/S
ASND
$ 221.88 -0.87 % $ 5 B danmarkDanmark
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Axsome Therapeutics Axsome Therapeutics
AXSM
$ 156.92 -1.23 % $ 7.81 B usaUSA
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Pharming Group N.V. Pharming Group N.V.
PHAR
$ 15.36 -0.71 % $ 7.59 B niderlandNiderland
Autolus Therapeutics plc Autolus Therapeutics plc
AUTL
$ 1.37 -4.2 % $ 350 M britainBritain
Kamada Ltd. Kamada Ltd.
KMDA
$ 8.5 -1.39 % $ 260 M israelIsrael
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Benitec Biopharma Benitec Biopharma
BNTC
$ 10.98 -4.52 % $ 452 M usaUSA
Inventiva S.A. Inventiva S.A.
IVA
$ 5.78 -4.3 % $ 138 M franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.09 -0.95 % $ 195 M israelIsrael
Tiziana Life Sciences PLC Tiziana Life Sciences PLC
TLSA
$ 1.21 -3.97 % $ 71.5 M britainBritain
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
Applied Genetic Technologies Corporation Applied Genetic Technologies Corporation
AGTC
- - $ 26.5 M usaUSA
PainReform Ltd. PainReform Ltd.
PRFX
$ 2.28 -0.44 % $ 1.03 M israelIsrael
Acorda Therapeutics Acorda Therapeutics
ACOR
- -24.86 % $ 820 K usaUSA
Acasti Pharma Acasti Pharma
ACST
- 4.01 % $ 150 M canadaCanada
Foghorn Therapeutics Foghorn Therapeutics
FHTX
$ 5.0 2.25 % $ 315 M usaUSA
Институт стволовых клеток человека Институт стволовых клеток человека
ISKJ
- - - russiaRussia
Adverum Biotechnologies Adverum Biotechnologies
ADVM
- - $ 86.2 M usaUSA
Acer Therapeutics Acer Therapeutics
ACER
- 2.71 % $ 14 M usaUSA
Advaxis Advaxis
ADXS
- -9.65 % $ 45.9 M usaUSA
AbCellera Biologics AbCellera Biologics
ABCL
$ 3.4 -3.68 % $ 1.02 B canadaCanada
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 54.13 -1.64 % $ 10.4 B usaUSA
Curis Curis
CRIS
$ 0.77 1.89 % $ 4.86 M usaUSA
Bellerophon Therapeutics Bellerophon Therapeutics
BLPH
- -74.18 % $ 955 K usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Coherus BioSciences Coherus BioSciences
CHRS
$ 1.52 -5.59 % $ 178 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
Burford Capital Limited Burford Capital Limited
BUR
$ 7.7 -5.87 % $ 1.29 B britainBritain
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
Cellectis S.A. Cellectis S.A.
CLLS
$ 3.34 -4.02 % $ 116 M franceFrance
Arbutus Biopharma Corporation Arbutus Biopharma Corporation
ABUS
$ 4.24 -2.97 % $ 704 M canadaCanada
Akouos Akouos
AKUS
- 0.23 % $ 488 M usaUSA
Albireo Pharma Albireo Pharma
ALBO
- -0.23 % $ 916 M usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Cardiff Oncology Cardiff Oncology
CRDF
$ 1.8 -1.1 % $ 120 M usaUSA
Allakos Allakos
ALLK
- - $ 28.6 M usaUSA
Cabaletta Bio Cabaletta Bio
CABA
$ 2.94 -3.29 % $ 3.43 M usaUSA
Iterum Therapeutics Iterum Therapeutics
ITRM
$ 0.16 -5.45 % $ 3.15 M irlandaIrlanda
Brickell Biotech Brickell Biotech
BBI
- -5.38 % $ 6.06 M usaUSA
Allena Pharmaceuticals Allena Pharmaceuticals
ALNA
- 3.16 % $ 1.9 M usaUSA